Legend Biotech Net Worth
Legend Biotech Net Worth Breakdown | LEGN |
Legend Biotech Net Worth Analysis
Legend Biotech's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Legend Biotech's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Legend Biotech's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Legend Biotech's net worth analysis. One common approach is to calculate Legend Biotech's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Legend Biotech's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Legend Biotech's net worth. This approach calculates the present value of Legend Biotech's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Legend Biotech's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Legend Biotech's net worth. This involves comparing Legend Biotech's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Legend Biotech's net worth relative to its peers.
Enterprise Value |
|
To determine if Legend Biotech is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Legend Biotech's net worth research are outlined below:
| Legend Biotech Corp had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 285.14 M. Net Loss for the year was (518.25 M) with loss before overhead, payroll, taxes, and interest of (284.01 M). | |
| Legend Biotech Corp currently holds about 791.26 M in cash with (384.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.11. | |
| Latest headline from globenewswire.com: Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia |
Legend Biotech uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Legend Biotech Corp. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Legend Biotech's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 16th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Legend Biotech Target Price Consensus
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Legend target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Legend Biotech's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 21 | Strong Buy |
Most Legend analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Legend stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Legend Biotech Corp, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationLegend Biotech Target Price Projection
Legend Biotech's current and average target prices are 49.58 and 88.36, respectively. The current price of Legend Biotech is the price at which Legend Biotech Corp is currently trading. On the other hand, Legend Biotech's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Legend Biotech Market Quote on 7th of October 2024
Target Price
Analyst Consensus On Legend Biotech Target Price
Know Legend Biotech's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Legend Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Legend Biotech Corp backward and forwards among themselves. Legend Biotech's institutional investor refers to the entity that pools money to purchase Legend Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Millennium Management Llc | 2024-06-30 | 1.7 M | Federated Hermes Inc | 2024-06-30 | 1.5 M | Citadel Advisors Llc | 2024-06-30 | 1.4 M | Paradigm Biocapital Advisors Lp | 2024-06-30 | 1.2 M | Timessquare Capital Management, Llc | 2024-06-30 | 1.2 M | State Street Corp | 2024-06-30 | 1.1 M | Alliancebernstein L.p. | 2024-06-30 | 1.1 M | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-06-30 | 1.1 M | Matthews International Cap Mgmt Llc | 2024-06-30 | 1 M | Fmr Inc | 2024-06-30 | 17.6 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 11.5 M |
Follow Legend Biotech's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 9.04 B.Market Cap |
|
Project Legend Biotech's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.31) | (0.32) | |
| Return On Capital Employed | (0.27) | (0.28) | |
| Return On Assets | (0.28) | (0.29) | |
| Return On Equity | (0.41) | (0.43) |
When accessing Legend Biotech's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Legend Biotech's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Legend Biotech's profitability and make more informed investment decisions.
Evaluate Legend Biotech's management efficiency
Legend Biotech Corp has return on total asset (ROA) of (0.1252) % which means that it has lost $0.1252 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2221) %, meaning that it created substantial loss on money invested by shareholders. Legend Biotech's management efficiency ratios could be used to measure how well Legend Biotech manages its routine affairs as well as how well it operates its assets and liabilities. As of the 7th of October 2024, Return On Tangible Assets is likely to drop to -0.32. In addition to that, Return On Capital Employed is likely to drop to -0.28. At this time, Legend Biotech's Fixed Asset Turnover is very stable compared to the past year.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.15 | 7.51 | |
| Tangible Book Value Per Share | 6.27 | 6.58 | |
| Enterprise Value Over EBITDA | (22.87) | (24.01) | |
| Price Book Value Ratio | 8.47 | 8.04 | |
| Enterprise Value Multiple | (22.87) | (24.01) | |
| Price Fair Value | 8.47 | 8.04 | |
| Enterprise Value | 9.6 B | 5.2 B |
The analysis of Legend Biotech's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Legend Biotech's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Legend Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Enterprise Value Revenue 17.7338 | Revenue 456 M | Quarterly Revenue Growth 1.544 | Revenue Per Share 2.505 | Return On Equity (0.22) |
Legend Biotech Corporate Filings
6K | 27th of September 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
13A | 5th of April 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 19th of March 2024 Other Reports | ViewVerify |
Legend Biotech Earnings Estimation Breakdown
The calculation of Legend Biotech's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Legend Biotech is estimated to be -0.43 with the future projection ranging from a low of -0.64 to a high of -0.24. Please be aware that this consensus of annual earnings estimates for Legend Biotech Corp is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.64 Lowest | Expected EPS | -0.24 Highest |
Legend Biotech Earnings Projection Consensus
Suppose the current estimates of Legend Biotech's value are higher than the current market price of the Legend Biotech stock. In this case, investors may conclude that Legend Biotech is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Legend Biotech's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of September 2024 | Current EPS (TTM) | |
| 0 | 58.06% | -0.1 | -0.43 | -1.54 |
Legend Biotech Earnings per Share Projection vs Actual
Actual Earning per Share of Legend Biotech refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Legend Biotech Corp predict the company's earnings will be in the future. The higher the earnings per share of Legend Biotech, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Legend Biotech Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Legend Biotech, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Legend Biotech should always be considered in relation to other companies to make a more educated investment decision.Legend Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Legend Biotech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-09 | 2024-06-30 | -0.38 | -0.1 | 0.28 | 73 | ||
2024-05-13 | 2024-03-31 | -0.34 | -0.16 | 0.18 | 52 | ||
2024-03-11 | 2023-12-31 | -0.83 | -0.8 | 0.03 | 3 | ||
2023-11-20 | 2023-09-30 | -0.68 | -0.34 | 0.34 | 50 | ||
2023-08-15 | 2023-06-30 | -0.6 | -1.14 | -0.54 | 90 | ||
2023-05-18 | 2023-03-31 | -0.78 | -0.68 | 0.1 | 12 | ||
2023-03-30 | 2022-12-31 | -0.44 | -0.62 | -0.18 | 40 | ||
2022-12-14 | 2022-09-30 | -0.31 | -0.37 | -0.06 | 19 | ||
2022-08-05 | 2022-06-30 | -0.3102 | -0.33 | -0.0198 | 6 | ||
2022-06-01 | 2022-03-31 | -0.46 | -0.26 | 0.2 | 43 | ||
2022-03-18 | 2021-12-31 | -0.41 | -0.3 | 0.11 | 26 | ||
2021-11-16 | 2021-09-30 | -0.35 | -0.43 | -0.08 | 22 | ||
2021-08-23 | 2021-06-30 | -0.34 | -0.32 | 0.02 | 5 | ||
2021-05-18 | 2021-03-31 | -0.35 | -0.3 | 0.05 | 14 | ||
2021-03-18 | 2020-12-31 | -0.28 | -0.22 | 0.06 | 21 | ||
2020-11-16 | 2020-09-30 | -0.31 | -0.5 | -0.19 | 61 | ||
2020-08-28 | 2020-06-30 | -0.26 | -1.26 | -1.0 | 384 | ||
2020-06-08 | 2020-03-31 | 0 | -0.51 | -0.51 | 0 |
Legend Biotech Corporate Management
| Elaine Qian | VP Resources | Profile | |
| James JD | General Counsel | Profile | |
| Lori CPA | Chief Officer | Profile | |
| Guowei Fang | Chief Development | Profile | |
| Tina Carter | Corporate Lead | Profile | |
| Steven Gavel | US Development | Profile | |
| Marc Harrison | VP Counsel | Profile |
Additional Information and Resources on Investing in Legend Stock
When determining whether Legend Biotech Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Legend Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Legend Biotech Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Legend Biotech Corp Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Legend Biotech Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Legend Biotech. If investors know Legend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Legend Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.54) | Revenue Per Share 2.505 | Quarterly Revenue Growth 1.544 | Return On Assets (0.13) | Return On Equity (0.22) |
The market value of Legend Biotech Corp is measured differently than its book value, which is the value of Legend that is recorded on the company's balance sheet. Investors also form their own opinion of Legend Biotech's value that differs from its market value or its book value, called intrinsic value, which is Legend Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Legend Biotech's market value can be influenced by many factors that don't directly affect Legend Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Legend Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Legend Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Legend Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.